Kiniksa Pharmaceuticals (KNSA) Financials

$26.89 +0.94 (+3.62%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$26.90 +0.00 (+0.02%)

As of 05/23/2025 07:58 PM Eastern

Annual Income Statements for Kiniksa Pharmaceuticals

This table shows Kiniksa Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Income / (Loss) Attributable to Common Shareholders	-43	14	183	-158	-161	-162	-103	-65
Consolidated Net Income / (Loss)	-43	14	183	-158	-161	-162	-103	-65
Net Income / (Loss) Continuing Operations	-43	14	183	-158	-161	-162	-103	-65
Total Pre-Tax Income	-36	-17	11	-157	-156	-164	-103	-65
Total Operating Income	-46	-25	9.77	-157	-157	-170	-108	-65
Total Gross Profit	234	180	173	29	0.00	0.00	0.00	0.00
Total Revenue	423	270	220	39	0.00	0.00	0.00	0.00
Operating Revenue	423	270	220	39	0.00	0.00	-	-
Total Cost of Revenue	189	90	47	9.94	0.00	0.00	0.00	0.00
Operating Cost of Revenue	189	90	47	9.94	0.00	0.00	-	-
Total Operating Expenses	280	206	163	185	157	170	108	65
Selling, General & Admin Expense	168	129	98	86	45	35	22	9.04
Research & Development Expense	112	76	65	99	112	135	87	56
Total Other Income / (Expense), net	9.46	8.54	1.25	0.10	1.13	6.05	4.72	0.53
Other Income / (Expense), net	9.46	8.54	1.25	0.10	1.13	-	-	-
Income Tax Expense	7.04	-31	-172	1.39	5.15	-2.05	-0.21	0.00
Basic Earnings per Share	($0.60)	$0.20	$2.64	($2.30)	($2.61)	($2.99)	($3.49)	($35.85)
Weighted Average Basic Shares Outstanding	71.42M	70.06M	69.38M	68.58M	61.84M	54.05M	29.55M	1.81M
Diluted Earnings per Share	($0.60)	$0.20	$2.60	($2.30)	($2.61)	($2.99)	($3.49)	($35.85)
Weighted Average Diluted Shares Outstanding	71.42M	71.92M	70.42M	68.58M	61.84M	54.05M	29.55M	1.81M
Weighted Average Basic & Diluted Shares Outstanding	145.29M	141.23M	139.51M	138.21M	61.84M	54.05M	29.55M	1.81M

This table shows Kiniksa Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	8.54	-8.90	-13	-3.99	-18	25	-14	15	-12	4.46	224
Consolidated Net Income / (Loss)	8.54	-8.89	-13	-3.91	-18	25	-14	15	-12	4.46	224
Net Income / (Loss) Continuing Operations	8.54	-8.89	-13	-3.91	-18	25	-14	15	-12	4.46	224
Total Pre-Tax Income	16	-17	-7.20	2.30	-14	2.45	-8.50	-1.24	-9.36	6.84	47
Total Operating Income	13	-19	-9.66	-0.12	-17	0.08	-11	-3.15	-11	6.05	46
Total Gross Profit	76	56	63	66	48	57	41	50	33	48	88
Total Revenue	138	123	112	109	80	83	67	71	48	62	99
Operating Revenue	138	123	112	109	80	83	67	71	48	62	99
Total Cost of Revenue	62	66	49	42	31	27	26	22	15	14	12
Operating Cost of Revenue	62	66	49	42	31	27	26	22	15	14	12
Total Operating Expenses	63	76	72	66	65	57	52	53	44	42	41
Selling, General & Admin Expense	44	41	46	42	39	37	34	29	29	27	25
Research & Development Expense	19	35	26	24	26	20	17	24	15	14	16
Total Other Income / (Expense), net	2.29	2.32	2.46	2.42	2.27	2.37	2.43	1.92	1.83	0.79	0.32
Other Income / (Expense), net	2.29	2.32	2.46	2.42	2.27	2.37	2.43	1.92	1.83	0.79	0.32
Income Tax Expense	7.03	-8.09	5.49	6.21	3.43	-23	5.36	-16	2.91	2.38	-177
Basic Earnings per Share	$0.12	($0.11)	($0.18)	($0.06)	($0.25)	$0.37	($0.20)	$0.21	($0.18)	$0.06	$3.23
Weighted Average Basic Shares Outstanding	72.65M	71.42M	71.73M	71.00M	70.63M	70.06M	70.19M	69.92M	69.75M	69.38M	69.45M
Diluted Earnings per Share	$0.11	($0.11)	($0.18)	($0.06)	($0.25)	$0.37	($0.20)	$0.21	($0.18)	$0.07	$3.18
Weighted Average Diluted Shares Outstanding	76.15M	71.42M	71.73M	71.00M	70.63M	71.92M	70.19M	71.63M	69.75M	70.42M	70.55M
Weighted Average Basic & Diluted Shares Outstanding	145.94M	145.29M	144.40M	142.49M	141.88M	141.23M	140.68M	140.33M	139.80M	139.51M	139.06M

This table details how cash moves in and out of Kiniksa Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Change in Cash & Equivalents	76	-15	0.25	8.22	67	-25	27	-10
Net Cash From Operating Activities	26	13	5.81	-126	-137	-158	-81	-50
Net Cash From Continuing Operating Activities	26	13	5.81	-126	-137	-158	-81	-50
Net Income / (Loss) Continuing Operations	-43	14	183	-158	-161	-162	-103	-65
Consolidated Net Income / (Loss)	-43	14	183	-158	-161	-162	-103	-65
Depreciation Expense	1.70	2.34	2.40	2.36	2.41	2.07	0.29	0.03
Amortization Expense	0.44	-1.07	-0.08	0.66	0.12	-3.50	-1.42	0.00
Non-Cash Adjustments To Reconcile Net Income	38	-6.67	18	25	21	24	6.00	0.90
Changes in Operating Assets and Liabilities, net	29	4.61	-197	3.24	1.75	-19	17	14
Net Cash From Investing Activities	38	-30	-8.08	129	-23	49	-239	-0.07
Net Cash From Continuing Investing Activities	38	-30	-8.08	129	-23	49	-239	-0.07
Purchase of Property, Plant & Equipment	-0.28	-0.13	-0.11	-0.42	-0.28	-3.20	-5.29	-0.07
Purchase of Investments	-202	-205	-136	-157	-430	-489	-402	0.00
Sale of Property, Plant & Equipment	0.03	0.00	0.09	0.00	0.00	-	-	-
Sale and/or Maturity of Investments	240	176	128	306	407	541	168	0.00
Net Cash From Financing Activities	12	1.50	2.52	5.89	227	84	347	40
Net Cash From Continuing Financing Activities	12	1.50	2.52	5.89	227	84	347	40
Issuance of Common Equity	17	3.70	3.42	5.89	228	84	159	0.00
Other Financing Activities, net	-4.98	-2.21	-0.90	0.00	0.00	-	0.38	0.00
Cash Income Taxes Paid	2.00	5.61	11	1.28	0.48	1.72	0.38	0.29

This table details how cash moves in and out of Kiniksa Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-26	86	-1.90	-42	33	-9.87	5.26	32	-42	-53	81
Net Cash From Operating Activities	22	19	-2.24	5.17	3.99	4.33	17	-3.74	-4.27	-12	62
Net Cash From Continuing Operating Activities	22	19	-2.26	5.19	3.99	4.33	17	-3.74	-4.27	-12	62
Net Income / (Loss) Continuing Operations	8.54	-8.89	-13	-3.91	-18	25	-14	15	-12	4.46	224
Consolidated Net Income / (Loss)	8.54	-8.89	-13	-3.91	-18	25	-14	15	-12	4.46	224
Depreciation Expense	0.35	0.40	0.40	0.43	0.47	0.54	0.60	0.60	0.60	0.60	0.49
Amortization Expense	0.26	0.82	-0.49	-0.19	0.30	-0.30	1.44	-1.15	-1.06	-0.20	-0.12
Non-Cash Adjustments To Reconcile Net Income	7.74	16	-7.26	22	6.70	-34	6.75	6.42	14	-1.28	6.02
Changes in Operating Assets and Liabilities, net	5.44	10	18	-13	14	12	22	-25	-5.33	-15	-168
Net Cash From Investing Activities	-52	65	-6.35	-47	26	-15	-12	36	-38	-43	19
Net Cash From Continuing Investing Activities	-52	65	-6.35	-47	26	-15	-12	36	-38	-43	19
Purchase of Property, Plant & Equipment	-0.10	-0.19	-	-	-0.08	-0.06	-0.02	-0.03	-0.02	0.03	-0.02
Purchase of Investments	-95	-22	-54	-89	-36	-61	-53	-38	-53	-63	-17
Sale and/or Maturity of Investments	44	87	48	42	62	46	41	74	15	20	36
Net Cash From Financing Activities	2.77	2.14	6.69	-0.18	3.61	0.70	0.55	0.16	0.09	1.19	0.36
Net Cash From Continuing Financing Activities	2.77	2.14	6.69	-0.18	3.61	0.70	0.55	0.16	0.09	1.19	0.36
Issuance of Common Equity	3.18	2.72	9.40	1.14	3.99	0.96	1.66	0.58	0.51	1.29	0.57
Other Financing Activities, net	-0.41	-0.58	-2.71	-1.31	-0.38	-0.26	-1.11	-0.42	-0.42	-0.10	-0.21
Cash Income Taxes Paid	3.01	1.26	-0.77	1.51	0.00	-1.31	0.20	3.52	3.20	6.08	1.32

This table presents Kiniksa Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Total Assets	581	526	460	233	349	255	322	47
Total Current Assets	332	276	243	196	333	242	314	47
Cash & Equivalents	184	108	123	122	114	47	72	46
Short-Term Investments	60	98	68	60	209	186	235	0.00
Accounts Receivable	42	21	13	3.99	0.00	-	-	-
Inventories, net	26	31	22	3.68	0.00	-	-	-
Prepaid Expenses	20	18	11	6.59	9.56	8.25	6.45	1.44
Other Current Assets	0.00	0.00	7.66	0.00	-	-	-	-
Plant, Property, & Equipment, net	0.66	0.73	1.66	2.83	4.05	6.40	6.36	0.13
Total Noncurrent Assets	248	249	215	34	12	6.51	1.86	0.26
Intangible Assets	16	17	18	19	0.00	-	-	-
Noncurrent Deferred & Refundable Income Taxes	211	219	185	0.00	0.01	4.37	1.22	0.24
Other Noncurrent Operating Assets	21	13	11	14	12	2.14	0.64	0.03
Total Liabilities & Shareholders' Equity	581	526	460	233	349	255	322	47
Total Liabilities	142	87	64	48	38	29	43	17
Total Current Liabilities	101	64	47	45	32	28	43	17
Accounts Payable	2.04	8.25	7.90	1.87	0.50	5.69	11	1.22
Accrued Expenses	81	45	30	38	29	20	31	16
Current Deferred Revenue	0.00	0.31	0.00	-	-	-	-	-
Other Current Liabilities	18	10	9.06	4.93	2.14	1.72	0.22	0.00
Total Noncurrent Liabilities	41	24	16	2.94	5.68	1.28	0.14	0.00
Noncurrent Deferred Revenue	32	12	12	0.00	-	-	-	-
Other Noncurrent Operating Liabilities	9.69	12	4.46	2.94	5.68	1.28	0.14	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	438	439	396	185	312	225	279	-90
Total Preferred & Common Equity	438	439	396	185	312	225	279	-90
Total Common Equity	438	439	396	185	312	225	279	-90
Common Stock	960	917	888	861	829	581	473	1.29
Retained Earnings	-521	-478	-492	-675	-517	-356	-194	-91
Accumulated Other Comprehensive Income / (Loss)	-0.16	0.01	0.04	-0.07	-0.03	0.03	-0.00	0.00

This table presents Kiniksa Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	599	555	542	520	483	484	443	460
Total Current Assets	356	311	301	271	256	246	232	242
Cash & Equivalents	157	97	99	141	118	113	81	176
Short-Term Investments	111	126	119	72	83	72	107	25
Accounts Receivable	40	25	20	16	3.04	25	7.42	11
Inventories, net	22	29	35	27	26	24	23	15
Prepaid Expenses	25	34	27	14	26	12	13	15
Plant, Property, & Equipment, net	0.61	0.56	0.63	0.71	0.92	1.14	1.39	2.00
Total Noncurrent Assets	243	243	241	248	226	237	210	216
Intangible Assets	16	17	17	17	18	18	18	19
Noncurrent Deferred & Refundable Income Taxes	208	208	204	215	194	204	184	186
Other Noncurrent Operating Assets	19	19	20	16	15	16	7.55	12
Total Liabilities & Shareholders' Equity	599	555	542	520	483	484	443	460
Total Liabilities	142	118	107	88	78	73	53	76
Total Current Liabilities	97	96	84	64	53	47	37	56
Accounts Payable	1.98	8.33	7.39	5.63	1.01	0.65	1.39	1.47
Accrued Expenses	76	70	63	45	41	35	21	31
Other Current Liabilities	19	18	14	14	8.74	6.83	7.82	12
Total Noncurrent Liabilities	45	22	23	24	24	25	16	19
Noncurrent Deferred Revenue	32	12	12	12	12	12	12	14
Other Noncurrent Operating Liabilities	13	11	11	12	13	13	4.02	5.26
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	457	437	435	432	405	412	390	384
Total Preferred & Common Equity	457	437	435	432	405	412	390	384
Total Common Equity	457	437	435	432	405	412	390	384
Common Stock	970	949	935	928	908	901	894	881
Retained Earnings	-513	-512	-500	-496	-503	-489	-504	-496
Accumulated Other Comprehensive Income / (Loss)	-0.17	-0.04	-0.13	-0.05	-0.00	0.01	0.06	-0.07

This table displays calculated financial ratios and metrics derived from Kiniksa Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	56.61%	22.74%	471.24%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-121.18%	-215.23%	108.69%	0.12%	10.32%	-56.82%	-67.19%	0.00%
EBIT Growth	-117.10%	-251.02%	107.04%	-0.20%	8.08%	-57.14%	-65.38%	0.00%
NOPAT Growth	-81.04%	-110.85%	248.23%	0.46%	7.41%	-57.14%	-65.38%	0.00%
Net Income Growth	-406.68%	-92.32%	216.11%	2.14%	0.30%	-56.81%	-59.12%	0.00%
EPS Growth	-400.00%	-92.31%	213.04%	11.88%	12.71%	14.33%	90.27%	0.00%
Operating Cash Flow Growth	93.14%	129.05%	104.60%	7.50%	13.79%	-95.49%	-61.32%	0.00%
Free Cash Flow Firm Growth	112.85%	-10.91%	67.66%	-16.82%	23.52%	-119.77%	0.00%	0.00%
Invested Capital Growth	-16.20%	13.10%	7,147.57%	124.12%	-47.76%	71.62%	-79.75%	0.00%
Revenue Q/Q Growth	10.19%	8.65%	24.37%	94.68%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-118.58%	-41.96%	144.83%	9.78%	-13.57%	6.63%	0.00%	0.00%
EBIT Q/Q Growth	-116.18%	-35.81%	134.03%	9.73%	-14.00%	6.36%	0.00%	0.00%
NOPAT Q/Q Growth	-73.87%	-31.02%	816.49%	9.67%	-14.82%	6.36%	0.00%	0.00%
Net Income Q/Q Growth	-376.32%	310.46%	28.61%	9.89%	-15.67%	6.25%	0.00%	0.00%
EPS Q/Q Growth	-400.00%	300.00%	30.00%	11.20%	-11.54%	-239.72%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	128.47%	611.58%	486.88%	15.01%	-14.24%	2.14%	-5.55%	0.00%
Free Cash Flow Firm Q/Q Growth	120.79%	-30.23%	79.08%	11.97%	-9.78%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-8.64%	13.93%	12.14%	-79.55%	-99.75%	-16.43%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	55.29%	66.72%	78.67%	74.22%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-8.04%	-5.69%	6.06%	-398.30%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-10.78%	-9.32%	4.44%	-406.38%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-8.54%	-6.16%	5.01%	-406.13%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-10.21%	5.21%	83.28%	-409.72%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	119.48%	-84.58%	1,663.01%	100.88%	103.30%	98.75%	99.79%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	96.44%	95.64%	99.19%
Effective Tax Rate	0.00%	0.00%	-1,563.01%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-14.95%	-8.05%	155.99%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-9.94%	-24.03%	144.81%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	5.10%	11.43%	-92.89%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-9.85%	3.37%	63.10%	-63.55%	-60.06%	-64.15%	-66.74%	-215.80%
Cash Return on Invested Capital (CROIC)	2.68%	-20.35%	-38.56%	-4,380.75%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-6.53%	-3.38%	3.18%	-53.77%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-7.80%	2.86%	52.96%	-54.24%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-9.85%	3.37%	63.10%	-63.55%	-60.06%	-64.15%	-40.90%	643.96%
Return on Equity Simple (ROE_SIMPLE)	-9.85%	3.21%	46.29%	-85.35%	-51.74%	-71.81%	-36.96%	72.32%
Net Operating Profit after Tax (NOPAT)	-32	-18	163	-110	-110	-119	-76	-46
NOPAT Margin	-7.54%	-6.53%	73.81%	-284.47%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-5.01%	15.98%	11.18%	-19.09%	-18.39%	-15.87%	-15.59%	-41.82%
Return On Investment Capital (ROIC_SIMPLE)	-7.28%	-4.02%	41.03%	-	-	-	-	-
Cost of Revenue to Revenue	44.71%	33.28%	21.33%	25.78%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	39.70%	47.89%	44.49%	222.99%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	26.37%	28.16%	29.74%	257.62%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	66.07%	76.05%	74.23%	480.61%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-36	-17	11	-157	-156	-170	-108	-65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-34	-15	13	-154	-154	-171	-109	-65
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.51	5.62	5.26	8.76	7.71	5.39	9.95	0.00
Price to Tangible Book Value (P/TBV)	6.77	5.85	5.51	9.78	7.71	5.39	9.95	0.00
Price to Revenue (P/Rev)	6.75	9.13	9.46	42.07	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	175.20	11.36	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.57%	8.80%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	13.41	9.73	9.21	507.56	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	6.17	8.37	8.60	37.35	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	141.81	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	171.65	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	11.64	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	101.70	169.99	325.91	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	456.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.51	-0.48	-0.64	-1.02	-1.04	-1.07	-1.14	-1.52
Leverage Ratio	1.26	1.18	1.19	1.17	1.12	1.14	1.19	1.58
Compound Leverage Factor	1.26	1.18	1.19	1.17	1.12	1.10	1.14	1.57
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	398.41%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-298.41%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	11.80	16.55	19.25	15.04	35.95	21.87	38.11	-1.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	38.72%	398.41%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	3.30	4.34	5.16	4.38	10.46	8.68	7.37	2.70
Quick Ratio	2.84	3.58	4.32	4.15	10.16	8.39	7.22	2.61
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5.73	-45	-40	-124	-106	-139	-63	0.00
Operating Cash Flow to CapEx	10,194.05%	10,231.54%	41,478.57%	-30,433.25%	-48,244.52%	-4,944.40%	-1,531.42%	-72,781.16%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.76	0.55	0.64	0.13	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	13.44	15.93	26.46	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	6.58	3.41	3.72	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	606.36	225.97	98.03	11.20	0.00	0.00	0.00	0.00
Accounts Payable Turnover	36.80	11.14	9.62	8.38	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	27.16	22.91	13.80	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	55.44	106.99	98.21	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	9.92	32.76	37.95	43.55	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	72.69	97.13	74.05	-43.55	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	195	232	206	2.84	-12	-7.96	-28	-16
Invested Capital Turnover	1.98	1.23	2.11	-8.64	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-38	27	203	15	-3.80	20	-12	0.00
Enterprise Value (EV)	2,613	2,261	1,893	1,439	2,082	981	2,472	227
Market Capitalization	2,856	2,467	2,083	1,622	2,406	1,214	2,779	153
Book Value per Share	$3.04	$3.12	$2.85	$1.34	$2.29	$2.05	$2.82	($49.57)
Tangible Book Value per Share	$2.92	$3.00	$2.72	$1.20	$2.29	$2.05	$2.82	($49.57)
Total Capital	438	439	396	185	312	225	279	30
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-244	-206	-191	-182	-324	-233	-307	-46
Capital Expenditures (CapEx)	0.25	0.13	0.01	0.42	0.28	3.20	5.29	0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-12	6.26	5.39	-31	-22	-20	-36	-16
Debt-free Net Working Capital (DFNWC)	231	213	196	152	301	214	271	30
Net Working Capital (NWC)	231	213	196	152	301	214	271	30
Net Nonoperating Expense (NNE)	11	-32	-21	48	51	43	28	19
Net Nonoperating Obligations (NNO)	-244	-206	-191	-182	-324	-233	-307	-46
Total Depreciation and Amortization (D&A)	2.14	1.27	2.32	3.02	2.53	-1.43	-1.14	0.03
Debt-free, Cash-free Net Working Capital to Revenue	-2.94%	2.32%	2.45%	-79.34%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	54.62%	78.68%	89.02%	393.37%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	54.62%	78.68%	89.02%	393.37%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.60)	$0.20	$2.64	($2.30)	($2.61)	($2.99)	($3.49)	($35.85)
Adjusted Weighted Average Basic Shares Outstanding	71.42M	70.06M	69.38M	68.58M	136.46M	111.09M	108.66M	1.81M
Adjusted Diluted Earnings per Share	($0.60)	$0.20	$2.60	($2.30)	($2.61)	($2.99)	($3.49)	($35.85)
Adjusted Weighted Average Diluted Shares Outstanding	71.42M	71.92M	70.42M	68.58M	136.46M	111.09M	108.66M	1.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($2.61)	($2.99)	($3.49)	($35.85)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	145.29M	141.23M	139.51M	138.21M	61.84M	54.05M	29.55M	1.81M
Normalized Net Operating Profit after Tax (NOPAT)	-32	-18	6.84	-110	-110	-119	-76	-46
Normalized NOPAT Margin	-7.54%	-6.53%	3.11%	-284.47%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-8.54%	-6.16%	5.01%	-406.13%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-0.70%	-0.07%	-3.54%	0.00%

This table displays calculated financial ratios and metrics derived from Kiniksa Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	72.54%	46.93%	67.37%	51.99%	65.18%	34.76%	-32.37%	164.99%	50.19%	230.14%	719.64%
EBITDA Growth	219.63%	-685.00%	-12.92%	242.31%	-37.48%	-62.79%	-113.70%	90.35%	56.25%	120.44%	257.06%
EBIT Growth	209.03%	-793.02%	15.27%	285.96%	-52.46%	-64.19%	-118.19%	93.57%	59.79%	118.93%	252.40%
NOPAT Growth	162.88%	-1,719.11%	11.61%	108.99%	-47.75%	-78.84%	-103.44%	83.72%	51.99%	115.59%	1,136.71%
Net Income Growth	148.23%	-135.22%	8.39%	-126.10%	-44.29%	465.73%	-106.18%	174.93%	51.33%	112.28%	833.67%
EPS Growth	144.00%	-129.73%	10.00%	-128.57%	-38.89%	428.57%	-106.29%	172.41%	50.00%	113.21%	822.73%
Operating Cash Flow Growth	459.92%	333.99%	-113.16%	238.07%	193.44%	137.36%	-72.63%	52.16%	88.42%	38.70%	317.66%
Free Cash Flow Firm Growth	233.50%	192.55%	43.88%	104.93%	85.60%	86.87%	-153.47%	-1,016.23%	-521.60%	-398.34%	228.90%
Invested Capital Growth	-13.37%	-16.20%	4.50%	-4.56%	7.77%	13.10%	11.33%	1,382.82%	880.31%	7,147.57%	1,221.92%
Revenue Q/Q Growth	12.44%	9.20%	3.30%	36.03%	-4.24%	24.38%	-6.19%	47.84%	-21.88%	-37.58%	267.55%
EBITDA Q/Q Growth	202.57%	-116.22%	-386.29%	118.84%	-601.60%	141.74%	-260.82%	81.80%	-235.76%	-84.63%	354.12%
EBIT Q/Q Growth	191.67%	-135.79%	-412.54%	116.14%	-682.69%	128.83%	-585.96%	86.77%	-236.88%	-85.36%	342.59%
NOPAT Q/Q Growth	153.90%	-99.82%	-3,506.65%	101.71%	-1,487.81%	110.91%	-246.45%	71.83%	-298.75%	-98.23%	1,741.51%
Net Income Q/Q Growth	196.07%	29.98%	-224.80%	77.93%	-170.15%	282.15%	-192.54%	222.02%	-375.05%	-98.01%	1,221.53%
EPS Q/Q Growth	200.00%	38.89%	-200.00%	76.00%	-167.57%	285.00%	-195.24%	216.67%	-357.14%	-97.80%	1,196.55%
Operating Cash Flow Q/Q Growth	18.93%	939.45%	-143.27%	29.62%	-7.82%	-74.54%	553.81%	12.28%	63.14%	-118.66%	893.11%
Free Cash Flow Firm Q/Q Growth	51.04%	251.47%	-251.48%	138.52%	-4.71%	8.15%	86.70%	-12.55%	4.52%	-474.10%	377.66%
Invested Capital Q/Q Growth	-2.91%	-8.64%	-1.44%	-0.92%	-6.08%	13.93%	-9.98%	11.88%	-1.43%	12.14%	1,099.03%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.25%	46.07%	55.96%	61.03%	60.70%	68.20%	60.63%	69.66%	68.30%	77.00%	88.34%
EBITDA Margin	11.73%	-12.86%	-6.50%	2.34%	-16.92%	3.23%	-9.63%	-2.50%	-20.33%	11.70%	47.52%
Operating Margin	9.63%	-15.75%	-8.61%	-0.11%	-20.71%	0.10%	-16.30%	-4.41%	-23.16%	9.77%	46.82%
EBIT Margin	11.30%	-13.86%	-6.42%	2.12%	-17.88%	2.94%	-12.68%	-1.73%	-19.37%	11.05%	47.14%
Profit (Net Income) Margin	6.20%	-7.25%	-11.31%	-3.60%	-22.17%	30.26%	-20.66%	20.95%	-25.38%	7.21%	226.05%
Tax Burden Percent	54.86%	52.35%	176.27%	-169.62%	124.01%	1,030.08%	163.02%	-1,208.39%	131.03%	65.21%	479.50%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	45.14%	0.00%	0.00%	269.62%	0.00%	-930.08%	0.00%	0.00%	0.00%	34.79%	-379.50%
Return on Invested Capital (ROIC)	12.48%	-21.84%	-11.09%	0.28%	-20.79%	1.23%	-14.65%	-7.17%	-34.32%	13.47%	403.19%
ROIC Less NNEP Spread (ROIC-NNEP)	11.96%	-23.90%	-8.30%	2.31%	-17.74%	-11.06%	-11.56%	-17.80%	-31.66%	13.19%	402.42%
Return on Net Nonoperating Assets (RNNOA)	-6.48%	12.26%	4.19%	-1.10%	8.65%	5.26%	5.89%	10.18%	18.95%	-8.46%	-269.76%
Return on Equity (ROE)	6.00%	-9.58%	-6.90%	-0.82%	-12.14%	6.49%	-8.77%	3.01%	-15.37%	5.01%	133.43%
Cash Return on Invested Capital (CROIC)	8.90%	2.68%	-13.20%	-4.03%	-17.64%	-20.35%	-17.67%	-5.20%	-8.63%	-38.56%	-194.88%
Operating Return on Assets (OROA)	9.72%	-10.60%	-4.75%	1.40%	-11.21%	1.61%	-6.69%	-1.40%	-13.59%	7.03%	23.42%
Return on Assets (ROA)	5.33%	-5.55%	-8.37%	-2.38%	-13.90%	16.59%	-10.90%	16.93%	-17.80%	4.58%	112.29%
Return on Common Equity (ROCE)	6.00%	-9.58%	-6.90%	-0.82%	-12.14%	6.49%	-8.77%	3.01%	-15.37%	5.01%	133.43%
Return on Equity Simple (ROE_SIMPLE)	-3.71%	0.00%	-2.08%	-2.35%	2.00%	0.00%	-1.65%	56.18%	50.32%	0.00%	37.13%
Net Operating Profit after Tax (NOPAT)	7.28	-14	-6.76	0.20	-12	0.83	-7.65	-2.21	-7.84	3.94	223
NOPAT Margin	5.28%	-11.02%	-6.02%	0.18%	-14.50%	1.00%	-11.41%	-3.09%	-16.21%	6.37%	224.49%
Net Nonoperating Expense Percent (NNEP)	0.52%	2.05%	-2.79%	-2.03%	-3.05%	12.29%	-3.09%	10.63%	-2.66%	0.28%	0.77%
Return On Investment Capital (ROIC_SIMPLE)	1.59%	-3.08%	-	-	-	0.19%	-	-	-	1.00%	-
Cost of Revenue to Revenue	44.75%	53.93%	44.04%	38.97%	39.30%	31.80%	39.37%	30.34%	31.70%	23.00%	11.66%
SG&A Expenses to Revenue	31.59%	33.08%	41.35%	39.03%	48.44%	44.05%	51.41%	40.82%	60.08%	43.98%	24.89%
R&D to Revenue	14.03%	28.74%	23.22%	22.11%	32.98%	24.04%	25.51%	33.25%	31.38%	23.25%	16.63%
Operating Expenses to Revenue	45.62%	61.82%	64.57%	61.14%	81.41%	68.10%	76.92%	74.07%	91.46%	67.23%	41.52%
Earnings before Interest and Taxes (EBIT)	16	-17	-7.20	2.30	-14	2.45	-8.50	-1.24	-9.36	6.84	47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	16	-16	-7.29	2.55	-14	2.69	-6.46	-1.79	-9.83	7.24	47
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.05	6.51	8.15	6.09	6.43	5.62	6.02	4.78	3.85	5.26	4.65
Price to Tangible Book Value (P/TBV)	7.31	6.77	8.47	6.33	6.69	5.85	6.29	5.00	4.03	5.51	4.88
Price to Revenue (P/Rev)	6.71	6.75	9.27	7.82	9.20	9.13	9.80	7.01	6.35	9.46	10.08
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	320.87	175.20	0.00	8.51	7.65	11.36	12.51
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.31%	0.57%	0.00%	11.75%	13.08%	8.80%	7.99%
Enterprise Value to Invested Capital (EV/IC)	15.64	13.41	15.65	11.23	11.73	9.73	10.96	7.87	6.48	9.21	8.64
Enterprise Value to Revenue (EV/Rev)	6.15	6.17	8.69	7.17	8.49	8.37	8.99	6.35	5.56	8.60	8.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	41.74	50.56	141.81	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	41.50	52.66	171.65	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.70	7.62	11.64	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	67.20	101.70	296.78	79.77	118.86	169.99	0.00	41.99	34.22	325.91	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	163.16	456.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.54	-0.51	-0.50	-0.48	-0.49	-0.48	-0.51	-0.57	-0.60	-0.64	-0.67
Leverage Ratio	1.26	1.26	1.23	1.21	1.17	1.18	1.20	1.23	1.21	1.19	1.19
Compound Leverage Factor	1.26	1.26	1.23	1.21	1.17	1.18	1.20	1.23	1.21	1.19	1.19
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	13.86	11.91	17.88	14.64	18.60	16.67	18.27	15.90	16.47	19.22	13.79
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.66	3.30	3.24	3.57	4.21	4.34	4.79	5.18	6.33	5.16	4.28
Quick Ratio	3.17	2.84	2.59	2.84	3.57	3.58	3.82	4.42	5.33	4.32	3.75
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	36	24	-16	11	-27	-26	-28	-214	-190	-199	53
Operating Cash Flow to CapEx	22,549.49%	9,725.39%	0.00%	0.00%	4,746.43%	7,723.21%	106,162.50%	-11,008.82%	-17,779.17%	0.00%	193,915.63%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.86	0.76	0.74	0.66	0.63	0.55	0.53	0.81	0.70	0.64	0.50
Accounts Receivable Turnover	17.17	13.44	27.51	15.03	25.77	15.93	35.03	17.30	12.82	26.46	24.62
Inventory Turnover	8.90	6.58	5.52	4.31	4.18	3.41	3.86	2.86	2.72	3.72	3.70
Fixed Asset Turnover	730.15	606.36	519.40	384.93	286.72	225.97	170.78	170.93	122.20	98.03	68.58
Accounts Payable Turnover	57.66	36.80	32.05	31.50	30.18	11.14	62.59	39.62	20.87	9.62	24.01
Days Sales Outstanding (DSO)	21.26	27.16	13.27	24.29	14.16	22.91	10.42	21.09	28.47	13.80	14.83
Days Inventory Outstanding (DIO)	41.03	55.44	66.17	84.76	87.30	106.99	94.50	127.50	134.26	98.21	98.61
Days Payable Outstanding (DPO)	6.33	9.92	11.39	11.59	12.09	32.76	5.83	9.21	17.49	37.95	15.20
Cash Conversion Cycle (CCC)	55.96	72.69	68.05	97.46	89.37	97.13	99.09	139.38	145.23	74.05	98.23
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	189	195	213	216	218	232	204	227	203	206	183
Invested Capital Turnover	2.36	1.98	1.84	1.53	1.43	1.23	1.28	2.32	2.12	2.11	1.80
Increase / (Decrease) in Invested Capital	-29	-38	9.18	-10	16	27	21	211	182	203	169
Enterprise Value (EV)	2,959	2,613	3,337	2,430	2,562	2,261	2,237	1,783	1,314	1,893	1,583
Market Capitalization	3,227	2,856	3,561	2,649	2,776	2,467	2,438	1,968	1,501	2,083	1,784
Book Value per Share	$3.15	$3.04	$3.07	$3.07	$6.11	$3.12	$2.89	$2.94	$2.80	$2.85	$2.76
Tangible Book Value per Share	$3.04	$2.92	$2.95	$2.95	$5.87	$3.00	$2.76	$2.82	$2.67	$2.72	$2.63
Total Capital	457	438	437	435	432	439	405	412	390	396	384
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-268	-244	-224	-219	-214	-206	-201	-185	-187	-191	-201
Capital Expenditures (CapEx)	0.10	0.19	0.00	0.00	0.08	0.06	0.02	0.03	0.02	-0.04	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.70	-12	-8.43	-2.03	-7.17	6.26	1.56	14	7.42	5.39	-15
Debt-free Net Working Capital (DFNWC)	259	231	215	217	206	213	203	199	195	196	185
Net Working Capital (NWC)	259	231	215	217	206	213	203	199	195	196	185
Net Nonoperating Expense (NNE)	-1.26	-4.62	5.93	4.11	6.12	-24	6.21	-17	4.43	-0.52	-1.54
Net Nonoperating Obligations (NNO)	-268	-244	-224	-219	-214	-206	-201	-185	-187	-191	-201
Total Depreciation and Amortization (D&A)	0.60	1.22	-0.09	0.24	0.76	0.24	2.04	-0.55	-0.47	0.40	0.37
Debt-free, Cash-free Net Working Capital to Revenue	-2.02%	-2.94%	-2.20%	-0.60%	-2.38%	2.32%	0.63%	4.83%	3.14%	2.45%	-8.70%
Debt-free Net Working Capital to Revenue	53.75%	54.62%	56.07%	63.95%	68.39%	78.68%	81.46%	70.71%	82.47%	89.02%	104.68%
Net Working Capital to Revenue	53.75%	54.62%	56.07%	63.95%	68.39%	78.68%	81.46%	70.71%	82.47%	89.02%	104.68%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.12	($0.11)	($0.18)	($0.06)	($0.25)	$0.37	($0.20)	$0.21	($0.18)	$0.06	$3.23
Adjusted Weighted Average Basic Shares Outstanding	72.65M	71.42M	71.73M	71.00M	70.63M	70.06M	70.19M	69.92M	69.75M	69.38M	69.45M
Adjusted Diluted Earnings per Share	$0.11	($0.11)	($0.18)	($0.06)	($0.25)	$0.37	($0.20)	$0.21	($0.18)	$0.07	$3.18
Adjusted Weighted Average Diluted Shares Outstanding	76.15M	71.42M	71.73M	71.00M	70.63M	71.92M	70.19M	71.63M	69.75M	70.42M	70.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	145.94M	145.29M	144.40M	142.49M	141.88M	141.23M	140.68M	140.33M	139.80M	139.51M	139.06M
Normalized Net Operating Profit after Tax (NOPAT)	7.28	-14	-6.76	-0.08	-12	0.06	-7.65	-2.21	-7.84	3.94	32
Normalized NOPAT Margin	5.28%	-11.02%	-6.02%	-0.08%	-14.50%	0.07%	-11.41%	-3.09%	-16.21%	6.37%	32.77%
Pre Tax Income Margin	11.30%	-13.86%	-6.42%	2.12%	-17.88%	2.94%	-12.68%	-1.73%	-19.37%	11.05%	47.14%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Kiniksa Pharmaceuticals' Financials

When does Kiniksa Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Kiniksa Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Kiniksa Pharmaceuticals' net income changed over the last 7 years?

Kiniksa Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$43.19 million in 2024, falling from -$64.87 million in 2017. The previous period was $14.08 million in 2023. View Kiniksa Pharmaceuticals' forecast to see where analysts expect Kiniksa Pharmaceuticals to go next.

What is Kiniksa Pharmaceuticals's operating income?

Kiniksa Pharmaceuticals's total operating income in 2024 was -$45.62 million, based on the following breakdown:

Total Gross Profit: $234.02 million
Total Operating Expenses: $279.63 million

How has Kiniksa Pharmaceuticals revenue changed over the last 7 years?

Over the last 7 years, Kiniksa Pharmaceuticals' total revenue changed from $0.00 in 2017 to $423.24 million in 2024, a change of 42,323,900,000.0%.

How much debt does Kiniksa Pharmaceuticals have?

Kiniksa Pharmaceuticals' total liabilities were at $142.12 million at the end of 2024, a 62.5% increase from 2023, and a 715.4% increase since 2017.

How much cash does Kiniksa Pharmaceuticals have?

In the past 7 years, Kiniksa Pharmaceuticals' cash and equivalents has ranged from $45.56 million in 2017 to $183.58 million in 2024, and is currently $183.58 million as of their latest financial filing in 2024.

How has Kiniksa Pharmaceuticals' book value per share changed over the last 7 years?

Over the last 7 years, Kiniksa Pharmaceuticals' book value per share changed from -49.57 in 2017 to 3.04 in 2024, a change of -106.1%.

Related Companies

This page (NASDAQ:KNSA) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals (KNSA) Financials

Frequently Asked Questions About Kiniksa Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals (KNSA) Financials

Annual Income Statements for Kiniksa Pharmaceuticals

Quarterly Income Statements for Kiniksa Pharmaceuticals

Annual Cash Flow Statements for Kiniksa Pharmaceuticals

Quarterly Cash Flow Statements for Kiniksa Pharmaceuticals

Annual Balance Sheets for Kiniksa Pharmaceuticals

Quarterly Balance Sheets for Kiniksa Pharmaceuticals

Annual Metrics And Ratios for Kiniksa Pharmaceuticals

Quarterly Metrics And Ratios for Kiniksa Pharmaceuticals

Frequently Asked Questions About Kiniksa Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools